CYP2C9: A Potential Drug Target for Benzodiazepines and Other Classes of Drugs

Target Name: CYP2C9

NCBI ID: G1559

CYP2C9

CYP2C9: A Potential Drug Target for Benzodiazepines and Other Classes of Drugs

CYP2C9, also known as monooxygenase D2, is a gene that encodes a protein located in the endoplasmic reticulum (ER) of the cell. The ER is a network of organelles responsible for the synthesis, processing, and storage of proteins. The CYP2C9 protein is a key player in the synthesis of a class of drugs called benzodiazepines, which are commonly used for the treatment of anxiety and insomnia.

The CYP2C9 gene was first identified in the late 1990s as a potential drug target for benzodiazepines. Since then, numerous studies have confirmed its involvement in the synthesis of these drugs, as well as its potential as a biomarker for the disease.

The CYP2C9 protein is a member of the superfamily of monooxygenases, which are a group of enzymes that produce reactive oxygen species (ROS) from oxygen-carrying molecules. In the case of CYP2C9, the protein is involved in the synthesis of 2-carboxy-1-naphthalene-1-carboxylic acid (2-Cn) from its precursor, 1-naphthalene-1-carboxylic acid (1-Cn).

The CYP2C9 gene is located on chromosome 11q22 and has been confirmed to have a single exon. The protein is expressed in most tissues of the body and is primarily localized to the ER. It is a 34-kDa protein that consists of 314 amino acids.

The CYP2C9 protein plays a crucial role in the synthesis of benzodiazepines. These drugs work by altering the activity of GABA receptors, which are involved in the regulation of anxiety and mood. By inhibiting the activity of GABA receptors, benzodiazepines can produce a range of effects, including anxiety and insomnia.

The CYP2C9 protein is also involved in the synthesis of other classes of drugs, including opioids and beta-blockers. These drugs work by modulating the activity of pain and anxiety receptors.

The CYP2C9 gene has been the focus of extensive research because of its potential as a drug target. Researchers have identified several potential drug targets for CYP2C9, including the interaction with GABA receptors, the modulation of pain perception, and the regulation of anxiety and depression.

One of the most promising potential drug targets for CYP2C9 is the interaction with GABA receptors. GABA is a neurotransmitter that plays a crucial role in the regulation of anxiety and depression. It is produced by the brain and is also synthesized in the liver by the enzyme GABA-伪-deficient 1 (GABA伪1). GABA伪1 is a potent inhibitor of GABA receptors and is involved in the pathophysiology of a wide range of neuropsychiatric and neurological disorders.

Research has shown that CYP2C9 is involved in the synthesis of GABA伪1 and that the CYP2C9 protein can modulate the activity of GABA伪1. This suggests that CYP2C9 may be a useful target for drugs that act on GABA receptors.

Another potential drug target for CYP2C9 is the modulation of pain perception. Pain is a complex physiological response that is involved in the regulation of tissue repair and regeneration. The CYP2C9 protein is involved in the synthesis of several pain modulators, including endogenous opioids and inflammatory mediators.

Research has shown that CYP2C9 is involved in the synthesis of endogenous opioids, which are natural pain modulators produced by the body. These opioids include enkeji, a potent endogenous opioid that is involved in the regulation of pain perception, and dihydrocannabinol (THC),

Protein Name: Cytochrome P450 Family 2 Subfamily C Member 9

Functions: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:7574697, PubMed:9866708, PubMed:9435160, PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:7574697, PubMed:15766564, PubMed:19965576, PubMed:9866708). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed:9866708, PubMed:9435160). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed:25994031)

The "CYP2C9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2C9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets